{"id":"desvenlafaxine-succinate-sustained-release-tablets","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the reuptake of serotonin and norepinephrine, desvenlafaxine succinate sustained release tablets increase the amount of these neurotransmitters available for use in the brain, which can help improve mood and reduce symptoms of depression and anxiety.","oneSentence":"Desvenlafaxine succinate sustained release tablets are a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of serotonin and norepinephrine in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:10.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Generalized anxiety disorder"}]},"trialDetails":[{"nctId":"NCT06270433","phase":"NA","title":"Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder","status":"RECRUITING","sponsor":"Jiangsu Province Nanjing Brain Hospital","startDate":"2024-02-19","conditions":"Anhedonia","enrollment":80},{"nctId":"NCT04364997","phase":"PHASE3","title":"Study of Desvenlafaxine in Treating Major Depressive Disorder.","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-06-18","conditions":"Major Depressive Disorder","enrollment":420},{"nctId":"NCT00669110","phase":"PHASE2","title":"Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-05","conditions":"Depressive Disorder, Major Depressive Disorder","enrollment":40},{"nctId":"NCT01372150","phase":"PHASE3","title":"A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-11-17","conditions":"Major Depressive Disorder","enrollment":340},{"nctId":"NCT00831415","phase":"PHASE3","title":"Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-03","conditions":"Major Depressive Disorder","enrollment":304},{"nctId":"NCT01371708","phase":"PHASE3","title":"A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02-02","conditions":"Major Depressive Disorder","enrollment":283},{"nctId":"NCT01371734","phase":"PHASE3","title":"A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-08","conditions":"Major Depressive Disorder","enrollment":363},{"nctId":"NCT01371721","phase":"PHASE3","title":"A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Major Depressive Disorder","enrollment":269},{"nctId":"NCT00887224","phase":"PHASE3","title":"Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-06","conditions":"Major Depressive Disorder","enrollment":874},{"nctId":"NCT01432457","phase":"PHASE4","title":"Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-10","conditions":"Major Depressive Disorder","enrollment":924},{"nctId":"NCT00445679","phase":"PHASE3","title":"Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-07","conditions":"Depressive Disorder, Major","enrollment":807},{"nctId":"NCT00369343","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-09","conditions":"Depression, Depressive Disorder, Depressive Disorder, Major","enrollment":381},{"nctId":"NCT01121484","phase":"PHASE4","title":"Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-06","conditions":"Major Depressive Disorder","enrollment":439},{"nctId":"NCT00384033","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-09","conditions":"Depressive Disorder, Major","enrollment":638},{"nctId":"NCT01056289","phase":"PHASE4","title":"Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-03","conditions":"Major Depressive Disorder","enrollment":480},{"nctId":"NCT01190514","phase":"PHASE1","title":"Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-09","conditions":"Depression - Major Depressive Disorder","enrollment":41},{"nctId":"NCT01443208","phase":"PHASE1","title":"Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-11","conditions":"Major Depressive Disorder","enrollment":36},{"nctId":"NCT00683800","phase":"PHASE3","title":"Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-06","conditions":"Vasomotor Symptoms","enrollment":2186},{"nctId":"NCT00952653","phase":"PHASE4","title":"Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-06","conditions":"Major Depressive Disorder","enrollment":28},{"nctId":"NCT00798707","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-12","conditions":"Major Depressive Disorder","enrollment":709},{"nctId":"NCT00863798","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-04","conditions":"Major Depressive Disorder","enrollment":682},{"nctId":"NCT00824291","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-02","conditions":"Depressive Disorder, Major","enrollment":437},{"nctId":"NCT00619619","phase":"PHASE2","title":"Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-02","conditions":"Depression, Major Depressive Disorder","enrollment":59},{"nctId":"NCT00277823","phase":"PHASE3","title":"Study Evaluating Desvenlafaxine Sustained-Release (DVS-SR) in Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-02","conditions":"Major Depressive Disorder","enrollment":480},{"nctId":"NCT00300378","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-03","conditions":"Depressive Disorder, Major","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DVS-233; Pristiq"],"phase":"phase_3","status":"active","brandName":"desvenlafaxine succinate sustained release tablets","genericName":"desvenlafaxine succinate sustained release tablets","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Desvenlafaxine succinate sustained release tablets are a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of serotonin and norepinephrine in the brain. Used for Major depressive disorder, Generalized anxiety disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}